About our research
The St John’s Institute at Guy’s and St Thomas’ has a world-leading reputation for patient care and dermatology research. Our research covers many areas including studies to understand the cause of skin conditions and clinical trials to test new treatments. Please see the research section to read more about how you can take part.
Through working closely with research groups at King's College London, we are a leading centre for research in skin disease in the UK. Our research programmes include: inflammatory dermatology, skin cancer, epidermolysis bullosa (EB) and paediatric dermatology. The Skin Therapy Research Unit in the Institute is a leader in psoriasis and eczema research.
We are currently looking for volunteers to take part in the following studies. Click on the headings below to find out more and see if you might be eligible to take part and help us with our research.
If you are interested in being a part of any of our research studies or would like more information, please email our team or call on 020 7188 9142 (or 020 7188 6273) between 9am and 5pm.
A pilot trial looking at whether installing water softeners in the homes of pregnant women reduces the risk of their babies developing atopic eczema.
We’re recruiting pregnant women living in hard water areas who are due to give birth at either St Thomas’ or Kingston Hospitals. The women, their partners or any other children they have, must have a history of either atopic eczema, asthma or hay fever.
Email: firstname.lastname@example.org or call 020 7188 7188 ext. 51601
A trial comparing a tablet treatment (Alitretinoin) and UV light treatment (PUVA) in patients with severe hand eczema, which is not adequately controlled on a daily basis with prescription steroid creams.
Evaluating the effectiveness of tralokinumab (a new treatment for eczema) combined with topical corticosteroids compared with placebo in treating moderate to severe atopic dermatitis.
A study set up to understand how eczema is inherited and why some people develop eczema and others do not. This may also identify possible factors that contribute to disease severity and treatment response.
A long term study assessing the benefit and safety of treatments for eczema.
A trial to determine the effectiveness of a drug called Anakinra (Kineret) in treating patients with a type of psoriasis called palmo-plantar pustulosis. You can find more details on the APRICOT website.
A trial to investigate how early treatment (within 12 month of disease onset) with a new therapy for psoriasis called Secukinumab compares against standard treatment with UV light therapy.
A study to find out what causes pustular forms of psoriasis. We are looking for patients with all forms of pustular psoriasis. Find out more about PLUM.
This stands for British Association of Dermatology Biologic Interventions Register and is a national registry set up to collect long-term safety data from patients on oral and injection treatments for psoriasis. If you are interested in taking part please get in touch via the BADBIR website.
A study to understand signals that may help us predict patient responses to different psoriasis treatments and facilitate personalisation of therapy.
Visit the BSTOP page for more details.
A study set up to understand why some patients respond well and some patients respond badly to psoriasis treatments. The aim of this is to facilitate personalisation of treatment in psoriasis and optimise effectiveness and safety. For more information, visit the PSORT website.
Read about ongoing studies. Please note we are no longer recruiting volunteers for these trials. Links to any overall study findings will be published as soon as they are made available.
This study was set up to understand how common eczema is in European, Canadian and US populations. Specifically, identifying how common mild, moderate and severe disease is, and how that corresponds with patient quality of life.
We are evaluating the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis.
Two different studies targeting different groups of patients with psoriasis. They were designed to assess the efficacy and safety of Secukinumab.
A research project looking at the influence of other medical conditions or co-morbidities on the outcomes of treatment in patients with moderate to severe psoriasis.
Is a registry of patients taking HUMIRA® for Psoriasis and collects information about medical history and experiences with the drug.
Read about past studies. Please note we are no longer recruiting volunteers for these trials.
A trial which found that Dupilumab combined with topical corticosteroids significantly improved signs and symptoms of atopic dermatitis. The quality of life improved in adults with a history of inadequate response to/intolerance of Ciclosporin A. Read the results.
SOLE OLE, SOLO2 and SOLO CONTINUE
These trials were designed to assess the effectiveness and safety of Dupilumab (a new treatment for eczema) in treating moderate to severe eczema. The results of these trials have since been published. Read the results.
This study was performed to assess the efficacy and safety of Lebrikizumab in treating eczema. When combined with topical corticosteroids there was a significant improvement and was well tolerated in patients with moderate-to-severe atopic dermatitis. Read the results.
We collected patient skin samples to investigate the role of skin microorganisms (e.g. bacteria) in the development of atopic dermatitis and psoriasis. Read the results.
Our research team
Professor Jonathan Barker – co-director
Professor Catherine Smith – co-director
Dr Andrew Pink – dermatologist
Balathas Thirugnanabalan – dermatology research manager
Learn more about our research nurses.
To contact us, please email our team or call on 020 7188 9142 (or 020 7188 6273) between 9am and 5pm.
Patient and public involvement meetings
We have an active patient and public involvement (PPI) group which meets to discuss the latest developments in psoriasis clinic and research. If you would like to join us, please email email@example.com. Here is an example of our PPI meeting minutes.